Condition category
Mental and Behavioural Disorders
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
A majority of patients with a psychiatric disorder such as major depressive disorder (MDD), schizophrenia or obsessive-compulsive disorder (OCD), suffers from cognitive dysfunction (e.g. in attention, memory, and planning ability). Cognitive dysfunction can play a major role in functional capacity and independence in everyday activities. Improving cognitive functioning in patients with psychiatric disorders may lead to maintenance or earlier return to employment and independent living and therefore to reduced healthcare and economic burden. Availability of interventions to improve cognitive dysfunction is limited. The companies MyCognition and Preloaded have developed AquaSnap which is designed to enhance and sustain performance leading to reduction in cognitive deficits. A potential advantage of AquaSnap over and above existing cognitive remediation test batteries is that more subjects comply with treatment because playing the game is enjoyable. The aim of this study is to investigate a newly developed online cognitive game (AquaSnap) to help psychiatric patients to improve their cognitive functioning.

Who can participate?
Adults aged 16 to 55 years old who have a diagnosis of schizophrenia/schizoaffective disorder, obsessive compulsive disorder or major depressive disorder

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group receive treatment as usual. Those in the second group receive treatment as usual as well as are given 12 weeks of cognitive training through playing AquaSnap. They are asked for play for a minimum of one hour a week. The game has an incorporated new cognitive assessment tool that changes the difficulty level of the game. Participants are followed up 12 weeks after the study to assess their cognitive function and the severity of their symptoms.

What are the possible benefits and risks of participating?
The possible benefit is for the subject might be improved cognitive functions for those who have played the game. There are no expected risks or side effects related to participating.

Where is the study run from?
Academisch Medisch Centrum (Netherlands)

When is the study starting and how long is it expected to run for?
December 2013 to June 2017

Who is funding the study?
Academisch Medisch Centrum (Netherlands)

Who is the main contact?
Miss Anna Domen

Trial website

Contact information



Primary contact

Miss Anna Domen


Contact details

Academisch Medisch Centrum
Meibergdreef 5
1105 AZ
+31 208913671

Additional identifiers

EudraCT number number

Protocol/serial number

NL 46634.018.13

Study information

Scientific title

Cognitive remediation in psychiatric patients with an applied online cognitive game and assessment tool


The Cognition Game Study

Study hypothesis

We expect that subjects that play the cognitive game for 12 weeks improve more in cognitive functioning compared to subjects that were in the treatment as usual condition.

Ethics approval

The Medical Ethical Committee of the Academic Medical Center Amsterdam, 22/04/2014, ref: 2013_375#B2014352

Study design

Single center blind randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet


Cognitive impairment in psychiatric patients (we included subjects with schizophrenia/schizo-affective disorder, major depressive disorder and obsessive compulsive disorder


Participants are randomly assigned to either treatment as usual (TAU) or the intervention plus TAU. All recruited participants are randomly assigned after completion of screening and baseline measurement in a 1:1 ratio. The intervention group was asked to play the game at home for at least 1 hour a week for 12 weeks. The TAU group was not given any extra instructions, but was offered a chance to play the game after followup measurement was completed. Both groups returned to the clinic for final measurement at 12 weeks.

The intervention group receive 12 weeks of cognitive training through the means of a newly developed online cognitive game that could be played from home. Subjects were asked to play a minimum of 1 hour a week. The games are developed as an adaptable training, which means the speed and difficulty level of the game changes according to the level of the player. The difficulty and intensity of the game is adjusted to the MyCQ scores (an incorporated new cognitive assessment tool) of the player, so that more impaired domains are trained more intensively. The control group received treatment as usual and could play the game after the trial was finished.

AquaSnap has an aquatic team whereby players have to explore the ocean and take photographs of fish. The player can choose where to dive and complete missions while diving. Taking the best photographs and completing missions will give the player experience points and coins, which then can be used to discover new areas on the map where the player can dive deeper into the ocean and encounter more unique fish. To train each cognitive domain, specific tasks, or loops, have been developed. These loops represent different ways to photograph a fish and are focused on training one of the five key-domains of cognition, however some loops train more than one domain. A series of loops are combined into an underwater dive. The game gets more difficult as the player proceeds further into the ocean and unlocks new areas. AquaSnap is an adaptable training, which means the speed and difficulty level of the game changes according to the level of the player. The difficulty and intensity of the game is adjusted to the cognitive scores of the player, so that more impaired domains are trained more intensively. The game can be reached online and can be accessed either through a laptop, PC, smartphone or tablet.

Intervention type



Drug names

Primary outcome measure

Cognitive functioning is measured using CANTAB and MyCQ at baseline and 12 weeks after the intervention.

Secondary outcome measures

1. Cognitive functioning is asssessed using the MyCQ at week 4 and week 8
2. Severity of symptoms is measured using PANSS for psychotic patients, YBOCS for OCD patients and IDS for depressed patients at baseline and 12 weeks
3. Blood marker abnormalities is measured using blood collection at baseline
4. Electro-encephalogram (EEG) is measured using the P300 and Mismatch negativity and resting state at baseline and 12 weeks
5. Level of functioning is measured using GAF Score at baseline and 12 weeks
6. Cortisol level is measured using hair analysis at baseline and 12 weeks

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Ability to give informed consent
2. Where participants are of legal childhood age, consent will also be obtained from one of the participant’s parents. Both the parent and participant will be required to sign the consent form in such a case. It will be the investigator’s responsibility to determine whether a participant of legal childhood age has the capacity to consent to the study.
3. Age 16 - 55 years old
4. DSM-IV-TR diagnosis of schizophrenia/schizoaffective disorder, obsessive compulsive disorder or major depressive disorder
5. Fluent in Dutch
6. Clinically stable

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. High risk of suicide (score of 2 or more on HAM-D suicide item)
2. Unstable medical disorder
3. Having met the criteria for a substance abuse disorder in the last three months (measured by the MINI-plus)
4. History of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure)
5. Premorbid IQ < 70

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Academic Medical Center Amsterdam
Meibergdreef 5
1105 AZ

Sponsor information



Sponsor details

25 Moorgate
United Kingdom

Sponsor type




Funder type


Funder name

Academisch Medisch Centrum

Alternative name(s)

Academic Medical Center, AMC

Funding Body Type

private sector organisation

Funding Body Subtype

Universities (academic only)



Funder name


Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Analysis and write up of the results has started and we plan to submit a paper on the study effect to a peer-reviewed journal at the beginning of 2018. An article on the validaty of the new assessment tool developed in concurrence with the cognitive game (the MyCQ) has already been submitted.

IPD sharing statement:
An anonymized dataset will be available on reasonable request and deposited in a public online data repository as soon as possible (before the end of this year). To access the data before that time, one can contact me: Anna Domen, Dept. of Psychiatry Academic Medical Center Amsterdam, Netherlands, email:, tel: + 31(0) 208913671

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

09/12/2019: The following changes have been made: 1. The intention to publish date has been changed from 31/01/2018 to 30/06/2020. 2. The public contact's email address has been changed. 22/11/2019: No publications found, verifying study status with principal investigator.